Although isoprostanes generally act on smooth muscle via TXA 2 -selective prostanoid receptors (TPs), some suggest other prostanoid receptors or possibly even a novel isoprostaneselective receptor might be involved. We studied contractions to several isoprostanes in porcine pulmonary vasculature using organ bath techniques. 8-iso-prostaglandin E 2 (PGE 2 ) was the most potent and efficacious of the isoprostanes, with a log EC 50 of Ϫ7.0 Ϯ 0.2 in the pulmonary artery and Ϫ6.8 Ϯ 0.2 in the pulmonary vein. The responses to all the isoprostanes were essentially completely blocked by the TP receptor antagonist Ϫ5 M] but were antagonized by the less selective DP/EP 1 /EP 2 antagonist AH6809 (6-isopropoxy-9-oxoxanthene-2-carboxylic acid; 10 Ϫ5 M) or by cyclopiazonic acid (10 Ϫ5 M; depletes the internal Ca 2ϩ store). Our data indicate that, whereas 8-iso-PGE 2 constricts pulmonary vasculature primarily through TP receptors, a substantial portion of this response is also directed through EP 3 receptors or possibly a novel isoprostane receptor.
ence of ICI 192605 and only in the pulmonary vein. The EC 50 of these ICI 192605-insensitive responses was Ϫ6.1 Ϯ 0.2. Using a variety of prostanoid agonists, we found the pulmonary vein lacked excitatory PGF 2␣ -selective prostanoid receptor (FP) or PGD 2 -selective prostanoid receptor (DP) but expressed excitatory EP 3 receptors. The ICI 192605-insensitive responses to 8-iso-PGE 2 were unaffected by the EP 1 antagonist SC-19220 [8-chloro-debenz[b,f] [1,4]oxazepine-10(11H)-carboxy-(2-acetyl) hydrazine; 10
Ϫ5 M] but were antagonized by the less selective DP/EP 1 /EP 2 antagonist AH6809 (6-isopropoxy-9-oxoxanthene-2-carboxylic acid; 10 Ϫ5 M) or by cyclopiazonic acid (10 Ϫ5 M; depletes the internal Ca 2ϩ store). Our data indicate that, whereas 8-iso-PGE 2 constricts pulmonary vasculature primarily through TP receptors, a substantial portion of this response is also directed through EP 3 receptors or possibly a novel isoprostane receptor.
Isoprostanes are metabolites of polyunsaturated fatty acids, such as arachidonic acid, and are produced by peroxidative attack of lipid membranes. They accumulate to substantial levels in a wide variety of clinical and experimental settings associated with oxidative stress, including systemic and pulmonary (Jankov et al., 2000) hypertension, and during exposure to agents that are associated with hypertension, such as subpressor doses of angiotensin II (Haas et al., 1999; Reckelhoff et al., 2000) , inflammatory mediators (Jourdan et al., 1997b (Jourdan et al., , 1999 , and growth factors (Natarajan et al., 1996) . For this reason, they are used extensively as markers of oxidative stress in general and membrane lipid peroxidation in particular. However, they are much more than inert markers; there is a growing body of literature describing powerful biological effects of these autacoids on smooth muscle (Fukunaga et al., 1993a,b) , platelets (Longmire et al., 1994; Yin et al., 1994) , and endothelial cells (Yura et al., 1999) . We have previously characterized the effects of several different isoprostanes on pulmonary vascular smooth muscle, finding them to exert vasoconstriction via activation of tyrosine and Rho kinases (Janssen et al., 2001) .
The excitatory effects of 8-iso-PGE 2 and 8-iso-PGF 2␣ are sensitive to a wide variety of agents, which are structurally distinct but all exhibit TP-receptor blocking activity, including ICI 192605 [4(Z)-6-[(2,4,5-cis)2-(2-chlorophenyl)-4-(2-hydroxyphenyl)1,3-dioxan-5-yl]hexenoic acid] (Jourdan et al., 1997a; Janssen et al., 2000 Janssen et al., , 2001 , SQ 29548 (Banerjee et al., These studies were supported by operating funds from the Canadian Institutes of Health Research and the Ontario Thoracic Society, and a Scientist Award from the Medical Research Council of Canada. ICI 192605, 4(Z)-6-[(2,4 ,5-cis)2-(2-chlorophenyl)-4-(2-hydroxyphenyl)1,3-dioxan-5-yl]hexenoic acid; SC-19220, 8-chlorodibenz[b,f] [1,4]oxazepine-10(11H)-carboxy-(2-acetyl)hydrazide; AH6809, 6-isopropoxy-9-oxoxanthene-2-carboxylic acid; PG, prostaglandin; CPA, cyclopiazonic acid; SQ 29548, [1S-(1␣,2␤-(5Z) L 670596, (Ϫ)6,8-difluoro-9-p-methylsulfonyl benzyl-1,2,3,4-tetrahydrocarbazol-1-yl-acetic acid; L 657925, 9,11-dimethyl-methano-11,12-methano-16-(3-iodo-4-hydroxyl 
ABBREVIATIONS:
1992; Fukunaga et al., 1993b; Mohler et al., 1996; Elmhurst et al., 1997; John and Valentin, 1997; Wagner et al., 1997; Sametz et al., 2000) , L 657925 (Wagner et al., 1997) , L 670596 (Elmhurst et al., 1997; Wagner et al., 1997 ), GR 32191 (Elmhurst et al., 1997 Oliveira et al., 2000) , and BMS 180291 (Mohler et al., 1996) . Thus, the bulk of the data would strongly suggest that TP receptors are involved.
However, certain findings have prompted some to suggest that isoprostanes act through some other receptor, perhaps even a novel isoprostane-selective receptor. For example, in aortic smooth muscle, 8-iso-PGF 2␣ displaces the binding of TP receptor-acting ligands with much less potency (two to three orders of magnitude less) than the homoligands but stimulates IP 3 production and [
3 H]thymidine incorporation with a higher potency than TP agonists (Fukunaga et al., 1993a,b) . Binding experiments have indicated the presence of both low-affinity and high-affinity binding sites for 8-iso-PGF 2␣ (Fukunaga et al., 1993a (Fukunaga et al., , 1995 (Fukunaga et al., , 1997 Yura et al., 1999) , which could represent the TP receptor and a unique isoprostane receptor, respectively. Finally, astroglia, endothelial cells, and microvessel smooth muscle cells are all able to respond to the TP agonist U46619, whereas 8-iso-PGF 2␣ stimulates only the former two but not the smooth muscle cells (Hou et al., 2000) ; in platelets, 8-iso-PGF 2␣ is only a partial agonist on TP receptors Longmire et al., 1994; Yin et al., 1994) . Collectively, these data point toward another receptor for the isoprostanes distinct from the TP receptor. There are limited data that isoprostanes can act on other prostanoid receptors. 12-iso-PGF 2␣ is a powerful agonist for FP receptors (Kunapuli et al., 1997) , and there is evidence that some isoprostane responses may involve EP receptors (Elmhurst et al., 1997; Sametz et al., 2000; Unmack et al., 2001) . In this study, we examined the actions of isoprostanes on pulmonary vascular smooth muscle using a variety of agonists and antagonists of prostanoid receptors.
Materials and Methods
Preparation of Isolated Tissues and Single Cells. Lobes of lung were obtained from pigs (20 -90 kg) euthanized at a local abattoir and immediately put in ice-cold physiological solution for transport to the laboratory. After removing the overlying parenchyma and connective tissue, the pulmonary artery and vein were excised and cut into ring segments Ϸ4-to 5-mm long (o.d. Ϸ2-10 mm); no attempt was made to remove the endothelium.
Muscle Bath Technique. Ring segments were mounted into 3-ml muscle baths using stainless steel hooks inserted into the lumen. One hook was fastened to a Grass FT .03 force transducer using silk thread (Ethicon 4-0); the other was attached to a Plexiglas rod, which served as an anchor. Tissues were bathed in Krebs-Ringer buffer (see below for composition) containing indomethacin (10 M), bubbled with 95% O 2 /5% CO 2 , and maintained at 37°C; tissues were passively stretched to impose a preload tension of Ϸ1 g (determined to allow maximal responses). Isometric changes in tension were amplified, digitized (two samples per second), and recorded on-line (DigiMed System Integrator; MicroMed, Louisville, KY) for plotting on the computer. Tissues were equilibrated for 1 h before commencing the experiments, during which time the tissues were challenged with 60 mM KCl at least once to assess the functional state of each tissue. Tissues were then washed, and the preload was readjusted just prior to onset of the actual study (i.e., at the end of the equilibrium period).
Solutions and Chemicals. Tissues were studied using KrebsRinger buffer containing 116 mM NaCl, 4.2 mM KCl, 2.5 mM CaCl 2 , 1.6 mM NaH 2 PO 4 , 1.2 mM MgSO 4 , 22 mM NaHCO 3 , 11 mM Dglucose, bubbled to maintain pH at 7.4. Indomethacin (10 M) was also added to the latter to prevent generation of cyclooxygenase metabolites of arachidonic acid.
Isoprostanes and SC-19220 [8-chloro-dibenz[b,f] [1,4]oxazepine-10(11H)-carboxy-(2-acetyl)hydrazide] were purchased from Cayman Chemical (Ann Arbor, MI), and ICI 192605 was a gift from Zeneca Pharmaceuticals plc (Alderley Park, UK); all other chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Stock solutions (10 mM) were prepared in absolute ethanol (isoprostanes, U46619; prostanoids, AH6809) or dimethyl sulfoxide (ICI 192605, SC-19220, cyclopiazonic acid) ; the final bath concentration of dimethyl sulfoxide and ethanol did not exceed 0.1%, which we have found elsewhere to have little or no effect on mechanical activity.
Data Analysis. The maximal contraction (E max ) produced with the highest concentration and the half-maximum effective concentration (EC 50 ) for the isoprostanes were interpolated from the individual concentration-effect curves. The equilibrium dissociation constant (K B ) for ICI 192605 was calculated using the equation:
is the concentration of the antagonist and DR (dose ratio) is the ratio of EC 50 in the presence and absence of antagonist.
Responses were standardized relative to responses to either 60 mM KCl or to 10 Ϫ6 M U46619, as indicated and are reported as mean Ϯ S.E.M; n refers to the number of animals. Statistical comparisons were made using analysis of variance (with Newman-Keuls post hoc test), as appropriate; P Ͻ 0.05 was considered statistically significant.
Results
Excitatory Effects of Isoprostanes in Porcine Pulmonary Vein. We first examined the ability of various isoprostanes to elevate tone in porcine pulmonary vasculature; isoprostanes tested included 8-iso-PGE 1 , 8-iso-PGE 2 , 8-iso-PGF 1␣ , 8-iso-PGF 2␣ , and 8-iso-PGF 2␤ .
8-iso-PGE 2 was the most potent and efficacious of the isoprostanes (Fig. 1) . The log EC 50 values for 8-iso-PGE 2 in the artery and the vein were Ϫ7.0 Ϯ 0.2 and Ϫ6.8 Ϯ 0.2, respectively. Supramaximal concentrations of 8-iso-PGE 2 consistently reversed tone in the arterial segments but not the vein segments (Fig. 1) .
In both artery and vein, 8-iso-PGE 1 was much less potent than 8-iso-PGE 2 , requiring approximately 10-fold higher concentrations to evoke a similar response as 8-iso-PGE 2 (Fig.  1) , and the F-ring isoprostanes were generally even less effective, having little or no effect at micromolar concentrations and achieving only Ϸ50% KCl response at 10 Ϫ5 M (Fig.  1) .
Involvement of Both TP and Non-TP Receptors in Mediating Isoprostane Contractions. In many other smooth muscle preparations, the excitatory effects of isoprostanes are sensitive to antagonists of TP receptors (see Introduction). Therefore we examined the effect of the TP receptor antagonist ICI 192605 on isoprostane-evoked contractions in porcine pulmonary vein. Tissues were first preconstricted with the TP receptor agonist U46619 to standardize responses (10 Ϫ6 M) and treated with ICI 192605 (10 Ϫ6 M) for 20 min, after which the dose-response relationships for the different isoprostanes were reexamined (Fig. 2) .
ICI 192605 completely inhibited U46619-evoked tone (data not shown). This agent also blocked completely the responses to all the isoprostanes in the pulmonary artery, as well as those to 8-iso-PGF 1␣ and 8-iso-PGF 2␣ in the pulmonary vein. However, 8-iso-PGE 2 was still able to evoke a response of Ϸ25% that of the U46619 response (which is comparable with the response to 60 mM KCl) in the pulmonary vein pretreated with ICI 192605; likewise, 8-iso-PGF 2␤ could still evoke a response of Ϸ8% that of the U46619 response (Fig. 2) (Fig. 3A) ; K B values derived in the presence of 10 Ϫ9 , 10 Ϫ8 , or 10 Ϫ7 M ICI 192605 were 1.4 ϫ 10 Ϫ9 M, 2.9 ϫ 10 Ϫ9 M, and 2.5 ϫ 10 Ϫ9 M, respectively. Likewise, ICI 192605 displaced the 8-iso-PGE 2 dose-response relationship in similar fashion (Fig. 3B) . K B values of 2.1 ϫ 10 Ϫ9 and 1.9 ϫ 10 Ϫ9 M were obtained in the presence of 10
Ϫ9
and 10 Ϫ8 M ICI 192605, respectively. In fact, 10 Ϫ7 M ICI 192605 inhibited 8-iso-PGE 2 responses to such an extent that a distinct E max was not obtained; however, assuming an E max of 115% KCl (comparable with that for the other data), K B was 5.9 ϫ 10 Ϫ9 M. The potency of ICI 192605 against 8-iso-PGE 2 responses (log K B of Ϸ2-5 nM) argues strongly against the possibility that 8-iso-PGE 2 evokes constriction in the presence of 10 Ϫ6 M ICI 192605 by merely displacing the latter receptor blocker.
Involvement of Other Prostanoid Receptors in Mediating Non-TP Contractions. It may be that 8-iso-PGE 2 is able to evoke constriction in the presence of ICI 192605 through an action on some prostanoid receptor other than TP receptors. We therefore characterized the sensitivity of this preparation to various prostanoid receptor agonists to determine which other excitatory prostanoid receptors might be present. Agonists included prostaglandin D 2 , prostaglandin Fig. 1 . Isoprostane-evoked contractions in porcine pulmonary vasculature. Mean concentration-response relationships obtained in pulmonary artery (left) and pulmonary vein (right) in response to cumulative addition of 8-iso-PGE 1 (E), 8-iso-PGE 2 (Ⅺ), 8-iso-PGF 1␣ (F), 8-iso-PGF 2␣ (f), and 8-iso-PGF 2␤ (᭜). Responses are expressed as a percentage of the response to 60 mM KCl evoked in each tissue at the beginning of the study (n ϭ 4 -7).
Fig. 2. Sensitivity of isoprostaneevoked contractions to ICI 192605.
The concentration-response relationships for the isoprostanes were investigated in another group of pulmonary artery (left) and pulmonary vein (right) tissues pretreated with ICI 192605 (10 Ϫ6 M). Responses are expressed as a percentage of the response to U46619 (10 Ϫ6 M) evoked in each tissue at the beginning of the study (n ϭ 4 for pulmonary artery; n ϭ 7 to 9 for pulmonary vein).
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Janssen and Tazzeo at ASPET Journals on July 13, 2017 jpet.aspetjournals.org Downloaded from E 2 , prostaglandin F 2␣ , BW245C (DP-selective), sulprostone (EP 3 -selective), and fluprostenol (FP-selective). Tissues were pretreated with ICI 192605 (10 Ϫ6 M) to rule out confounding effects of these prostanoids on TP receptors.
Prostaglandins E 2 and F 2␣ were both able to markedly elevate tone, although the former autacoid was considerably more potent than the latter (Fig. 4) . PGE 2 responses increased in magnitude over the concentration range 10 Ϫ8 to 10 Ϫ6 M, with a log EC 50 value of Ϫ7.1 Ϯ 0.2, comparable with the published pD 2 value for PGE 2 acting at an EP receptor; at 10 Ϫ5 M, however, PGE 2 responses decreased in magnitude (i.e., PGE 2 seemed to cause relaxation). PGF 2␣ responses, on the other hand, increased in magnitude over the concentration range 10 Ϫ7 to 10 Ϫ5 M; since a plateau was not attained, we could not calculate an EC 50 value (but it is clearly greater than 1 M). Sulprostone was even more potent (EC 50 value of Ϫ7.2 Ϯ 0.2) and effective than both these prostaglandins, eliciting contractions nearly twice as large as those evoked by PGE 2 or PGF 2␣ .
Contractions were not evoked by fluprostenol, PGD 2 , or BW245C (Fig. 4) . In fact, the DP-selective agonists both evoked relaxations, with BW245C being particularly effective in this respect. Thus, the porcine pulmonary vein seems to be endowed with excitatory EP 3 and TP receptors, as well as inhibitory DP receptors, but not with FP receptors. Do Non-TP Contractions Involve EP Receptors? It may be, then, that 8-iso-PGE 2 is also acting through excitatory EP receptors, in addition to the TP receptors characterized above. EP 1 receptors couple to G q and phospholipase C and mediate excitation via IP 3 -induced Ca 2ϩ release, whereas EP 3 receptors couple to G i and thereby inhibit adenylate cyclase (Coleman et al., 1994; Narumiya et al., 1999) . We therefore examined the effect of the DP/EP 1 /EP 2 receptor antagonist AH6809 and the EP 1 -selective antagonist SC-19220, as well as the effect of depleting the internal Ca 2ϩ pool using cyclopiazonic acid. Tissues were pretreated with ICI 192605 (10 Ϫ6 M), and then with either AH6809 (10 Ϫ5 M), SC-19220 (10 Ϫ5 M), or with cyclopiazonic acid (10 Ϫ5 M) for 20 min, after which the 8-iso-PGE 2 dose-response relationship was reexamined.
SC-19220 had no statistically significant effect on the concentration-response relationships for 8-iso-PGE 2 or PGE 2 (Fig. 5) . The less selective blocker AH6809, however, had no effect on PGE 2 responses but significantly antagonized those evoked by 8-iso-PGE 2 (Fig. 6) . Isoprostane responses were abolished by cyclopiazonic acid (Fig. 6) . 
Discussion
For over a decade, isoprostanes have been recognized as being useful as markers of oxidative stress in clinical and experimental settings. Now it is also known that these autacoids exert powerful biological effects. Some have described the vasoconstrictor effects of 8-iso-PGF 2␣ on pulmonary vasculature (Hill et al., 1997; John and Valentin, 1997) and on other vascular beds (Mohler et al., 1996; Wagner et al., 1997; Oliveira et al., 2000) . However, very few have compared the effects of a wide range of isoprostanes, as we have done in this study. We found several E-and F-ring isoprostanes to increase tone in pulmonary vasculature to varying degrees. In particular, the most potent and efficacious of these was 8-iso-PGE 2 , much more so than 8-iso-PGF 2␣ , the isoprostane upon which most previous studies of isoprostane effects have focused solely. In fact, others have described vasodilatory responses to 8-iso-PGF 2␣ in the rat pulmonary artery (Jourdan et al., 1997a) . We were again struck by the very high degree of specificity in these actions of the isoprostanes; 8-iso-PGE 2 differs only very slightly from 8-iso-PGF 2␣ (a ketone versus a hydroxyl group, respectively, on the central cyclopentane ring) or from 8-iso-PGE 1 (two versus one unsaturated bonds, respectively) but differs tremendously with respect to biological activity. This argues strongly for a receptor-mediated mechanism, rather than some nonspecific mechanism such as altered membrane fluidity.
In general, isoprostanes seem to mediate their effects on vascular smooth muscle via TP receptors. Consistent with this, we found that nearly all the excitatory responses of the isoprostanes in the pulmonary vasculature were prevented by pre-exposure to the TP receptor blocker ICI 192605. Moreover, we obtained similar values of K B for ICI 192605 acting against U46619 (pK B Ϸ 1-2 nM) and against 8-iso-PGE 2 (2-5 nM), and both of these values compare favorably with published literature values for this antagonist (Narumiya et al., 1999) . These data indicate that, in the porcine pulmonary vein, ICI 192605, U46619, and 8-iso-PGE 2 compete at a common receptor. Although the actions of the other isoprostanes were essentially completely prevented by TP receptor blockade, this was not true of 8-iso-PGE 2 in the porcine pulmonary vein; only this isoprostane was able to evoke substantial contraction in the maintained presence of ICI 192605 (at concentrations three orders of magnitude above the K B value we obtained for this blocker in this preparation). Once again, this high degree of compound-related specificity speaks toward a receptormediated mechanism. Others have provided limited evidence that isoprostanes can activate other prostanoid receptors, including EP (Elmhurst et al., 1997; Sametz et al., 2000; Ungrin et al., 2001 ) and FP (Kunapuli et al., 1997) receptors.
8-iso-PGE 2 has been shown elsewhere to be only a partial agonist at TP receptors in the coronary artery (Kromer and Tippins, 1996) and in platelets Longmire et al., 1994; Yin et al., 1994) . If this were true also of the pulmonary vein, this might complicate interpretation of the effects of ICI 192605 on 8-iso-PGE 2 -evoked responses. We found, however, that in tissues studied concurrently with either the full TP agonist U46619 or with 8-iso-PGE 2 , the former evoked a peak response of Ϸ120% KCl, whereas the response to the latter was already Ϸ110% KCl before it reached a peak (we were unable to use sufficiently high concentrations to reach a peak). This observation is not consistent with partial agonism. Furthermore, partial agonism would not explain the different sensitivity of these responses to CPA; the responses that persist in the presence of ICI 192605 were completely eliminated by CPA (Fig. 6) , whereas the ICI 192605-sensitive responses are unaffected (Janssen et al., 2001 ). Thus, 8-iso-PGE 2 appears to be a full agonist at TP receptors in this tissue, and the ICI 192605-resistant component appears to be mediated through a non-TP receptor.
The non-TP-mediated effects of 8-iso-PGE 2 would not involve FP receptors; the FP-selective agonist fluprostenol was devoid of activity, indicating the absence of any functionally coupled FP receptors in the porcine pulmonary vein. Although PGF 2␣ did evoke contractions, the concentrations required to do so were considerably in excess of the literature pD 2 value for this prostanoid; instead, PGF 2␣ may be acting nonselectively through some other prostanoid receptor. The non-TP-mediated effects of 8-iso-PGE 2 also would not involve DP receptors, since the DP-selective agonists PGD 2 and BW245C evoked only relaxations. PGE 2 , however, was able to evoke substantial contractions with an EC 50 value of Ϸ100 nM, comparable with the published literature value for its action at EP receptors (Coleman et al., 1994; Ungrin et al., 2001) . Thus, in addition to its actions at the TP receptor, 8-iso-PGE 2 may also be acting at one of the four subtypes of EP receptors. PGE 2 and 8-iso-PGE 2 shared similar concentration-response characteristics; the threshold concentration for both is approximately 10 nM, and both evoke a response of approximately 20% U46619 response when applied at 1 M. At concentrations above 1 M, the PGE 2 responses reversed whereas those to 8-iso-PGE 2 continued to increase in magnitude at higher concentrations; as a result, the EC 50 values for these two compounds differed somewhat (Ϸ0.1 and Ϸ1.0 M, respectively). One interpretation of this finding is that PGE 2 might be acting nonselectively at the inhibitory DP receptors, whereas the isoprostane does not.
With respect to the subtype of EP receptor that might mediate the non-TP responses to isoprostanes, only two subtypes are generally associated with excitation in smooth muscle: EP 1 and EP 3 (Coleman et al., 1994) . Our data indicate that these tissues express excitatory EP 3 but not EP 1 receptors since 1) the EP 3 -selective agonist sulprostone was as potent (EC 50 value of Ϸ100 nM) and twice as effective as PGE 2 ; 2) the EP 1 -selective antagonist SC-19220 had no significant effect on PGE 2 -or 8-iso-PGE 2 -evoked responses; and 3) PGE 2 responses were also insensitive to the DP/EP 1 /EP 2 receptor antagonist AH6809. Strangely, 8-iso-PGE 2 -evoked contractions were significantly inhibited by AH6809. One interpretation of this paradoxical finding is that the isoprostane is acting through a novel isoprostane-selective receptor that is also sensitive to the relatively poorly selective blocker AH6809.
Whatever the type/subtype of non-TP receptor that mediates these ICI 192605-insensitive responses, it appears to trigger mobilization of intracellular Ca 2ϩ ; we found these contractions to be eliminated by pretreatment of the tissues with CPA, which effectively depletes the internal Ca 2ϩ pool. In a previous study of the effects of isoprostanes in human and canine pulmonary vasculature (Janssen et al., 2001) , CPA was largely ineffective against the TP receptor-mediated effects of 8-iso-PGE 2 .
In conclusion, we find that 8-iso-PGE 2 evokes vasoconstriction in the pulmonary vasculature via an action on TP receptors. In the pulmonary vein, 8-iso-PGE 2 can also act upon another type of excitatory receptor, likely EP 3 receptors or possibly a unique isoprostane receptor. This may represent an important mechanism during hypertension, which is characterized in part by production of large amounts of isoprostanes (Jankov et al., 2000; Romero and Reckelhoff, 2000) .
